Research article

Platelet-activating factor and oxidized phosphatidylcholines do not suppress endotoxin-induced pro-inflammatory signaling among human myeloid and endothelial cells

  • Received: 26 July 2017 Accepted: 10 October 2017 Published: 17 October 2017
  • Platelet-activating factor (PAF) and related phospholipid oxidation products termed oxidized phospholipids (OxPLs) promote inflammation. PAF is made in response to bacterial endotoxin-lipopolysaccharide (LPS) that is recognized by Toll-like receptor-4 (TLR-4) whose activation leads to translocation of transcription factor NF-ΚB to the nucleus—a key regulator of multiple pro-inflammatory genes including COX-2 and IL-8. Paradoxically, PAF and OxPLs are claimed to inhibit LPS-mediated signaling, questioning the very pro-inflammatory roles of PAF and OxPLs and anti-inflammatory nature of PAF-acetylhydrolase (PAF-AH), an enzyme that attenuates both PAF and OxPLs signaling. We investigated the effect of PAF and representative OxPLs: 1-palmitoyl-2-oxovaleroyl-sn-glycero-3-phosphocholine (POVPC), 1-palmitoyl-2-glutaroyl-sn- glycero-3-phosphocholine (PGPC) and 1-alkyl-2-butanoyl-sn-glycero-3-phosphocholine PAF (C4 PAF) on LPS-induced expression of NF-ΚB mediated inflammation in isolated human myeloid cells: polymorphonuclear leukocyte (PMNs), monocytes and human umbilical vein endothelial cells (HUVECs). Using intracellular calcium transients, we show that POVPC and PGPC dose-dependently activate the PAF-receptor (PAF-R) in PMNs, that can beblocked by the PAF-R antagonist WEB-2086 and rPAF-AH pre-treatment. All the three cell types express minute or no detectable COX-2 when stimulated with either PAF (0.1 µM) or OxPLs (0.1 µM) alone. While LPS (100 ng/mL) induced expression of COX-2 in all the cell types, pre-activation of PAF-R with PAF (0.1 µM) or OxPLs (0.1 µM) did not suppress LPS (100 ng/mL)-induced COX-2 expression and in fact we obresved incereased PGE2 levels in an NS-398 sensitive manner. In addition, pre-activation of PAF-R significantly augmented LPS (100 ng/mL)-induced IL-8 production in PMNs. Thus, PAF and OXPLs do not suppress the ability of LPS to exert its pro-inflammatory effects in isolated human vascular cells.

    Citation: Shancy Petsel Jacob, Chikkamenahalli Lakshminarayana Lakshmikanth, Thomas M. McIntyre, Gopal Kedihitlu Marathe. Platelet-activating factor and oxidized phosphatidylcholines do not suppress endotoxin-induced pro-inflammatory signaling among human myeloid and endothelial cells[J]. AIMS Allergy and Immunology, 2017, 1(3): 108-123. doi: 10.3934/Allergy.2017.3.108

    Related Papers:

  • Platelet-activating factor (PAF) and related phospholipid oxidation products termed oxidized phospholipids (OxPLs) promote inflammation. PAF is made in response to bacterial endotoxin-lipopolysaccharide (LPS) that is recognized by Toll-like receptor-4 (TLR-4) whose activation leads to translocation of transcription factor NF-ΚB to the nucleus—a key regulator of multiple pro-inflammatory genes including COX-2 and IL-8. Paradoxically, PAF and OxPLs are claimed to inhibit LPS-mediated signaling, questioning the very pro-inflammatory roles of PAF and OxPLs and anti-inflammatory nature of PAF-acetylhydrolase (PAF-AH), an enzyme that attenuates both PAF and OxPLs signaling. We investigated the effect of PAF and representative OxPLs: 1-palmitoyl-2-oxovaleroyl-sn-glycero-3-phosphocholine (POVPC), 1-palmitoyl-2-glutaroyl-sn- glycero-3-phosphocholine (PGPC) and 1-alkyl-2-butanoyl-sn-glycero-3-phosphocholine PAF (C4 PAF) on LPS-induced expression of NF-ΚB mediated inflammation in isolated human myeloid cells: polymorphonuclear leukocyte (PMNs), monocytes and human umbilical vein endothelial cells (HUVECs). Using intracellular calcium transients, we show that POVPC and PGPC dose-dependently activate the PAF-receptor (PAF-R) in PMNs, that can beblocked by the PAF-R antagonist WEB-2086 and rPAF-AH pre-treatment. All the three cell types express minute or no detectable COX-2 when stimulated with either PAF (0.1 µM) or OxPLs (0.1 µM) alone. While LPS (100 ng/mL) induced expression of COX-2 in all the cell types, pre-activation of PAF-R with PAF (0.1 µM) or OxPLs (0.1 µM) did not suppress LPS (100 ng/mL)-induced COX-2 expression and in fact we obresved incereased PGE2 levels in an NS-398 sensitive manner. In addition, pre-activation of PAF-R significantly augmented LPS (100 ng/mL)-induced IL-8 production in PMNs. Thus, PAF and OXPLs do not suppress the ability of LPS to exert its pro-inflammatory effects in isolated human vascular cells.


    加载中
    [1] Zimmerman GA, Lorant DE, McIntyre TM, et al. (1993) Juxtacrine intercellular signaling: another way to do it. Am J Resp Cell Mol Biol 9: 573–577. doi: 10.1165/ajrcmb/9.6.573
    [2] Raetz CR, Whitfield C (2002) Lipopolysaccharide endotoxins. Annu Rev Biochem 71: 635–700. doi: 10.1146/annurev.biochem.71.110601.135414
    [3] Beutler B, Rietschel ET (2003) Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 3: 169–176. doi: 10.1038/nri1004
    [4] Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135–145. doi: 10.1038/35100529
    [5] Hoffmann A, Baltimore D (2006) Circuitry of nuclear factor kappa B signaling. Immunol Rev 210: 171–186. doi: 10.1111/j.0105-2896.2006.00375.x
    [6] Oeckinghaus A, Ghosh S (2009) The NF-kappa B family of transcription factors and its regulation. CSH Perspect Biol 1: a000034.
    [7] Weyrich AS, McIntyre TM, McEver RP, et al. (1995) Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest 95: 2297–2303.
    [8] Yost CC, Weyrich AS, Zimmerman GA (2010) The platelet-activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie 92: 692–697. doi: 10.1016/j.biochi.2010.02.011
    [9] Brand K, Page S, Walli AK, et al. (1997) Role of nuclear factor‐kappa B in atherogenesis. Exp Physiol 82: 297–304. doi: 10.1113/expphysiol.1997.sp004025
    [10] Baker RG, Hayden MS, Ghosh S (2011) NF-kappa B, inflammation and metabolic disease. Cell Metab 13: 11–22. doi: 10.1016/j.cmet.2010.12.008
    [11] Prescott SM, Zimmerman GA, Stafforini DM, et al. (2000) Platelet-activating factor and related lipid mediators. Annu Rev Biochem 69: 419–445. doi: 10.1146/annurev.biochem.69.1.419
    [12] Mozes T, Heiligers JP, Tak CJ, et al. (1991) Platelet-activating factor is one of the mediators involved in endotoxic shock in pigs. J lipid Med 4: 309–325.
    [13] Koltai M, Hosford D, Braquet P (1993) PAF-induced amplification of mediator release in septic shock: prevention or downregulation by PAF antagonists. J Lipid Med 6: 183–198.
    [14] Shimizu T, Honda Z, Nakamura M, et al. (1992) Platelet-activating factor receptor and signal transduction. Biochem Pharmacol 44: 1001–1008. doi: 10.1016/0006-2952(92)90360-U
    [15] Marathe GK, Davies SS, Harrison KA, et al. (1999) Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J Biol Chem 274: 28395–28404. doi: 10.1074/jbc.274.40.28395
    [16] Marathe GK, Harrison KA, Murphy RC, et al. (2000) Bioactive phospholipid oxidation products. Free Radical Biol Med 28: 1762–1770.
    [17] Smiley PL, Stremler KE, Prescott SM, et al. (1991) Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem 266: 11104–11110.
    [18] Marathe GK, Prescott SM, Zimmerman GA, et al. (2001) Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovas Med 11: 139–142. doi: 10.1016/S1050-1738(01)00100-1
    [19] Leitinger N, Watson AD, Faull KF, et al. (1997) Monocyte binding to endothelial cells induced by oxidized phospholipids present in minimally oxidized low density lipoprotein is inhibited by a platelet-activating factor receptor antagonist. Adv Expt Med Biol 433: 379–382. doi: 10.1007/978-1-4899-1810-9_82
    [20] Chen R, Chen X, Salomon RG, et al. (2009) Platelet activation by low concentrations of intact oxidized LDL particles involves the PAF receptor. Arterioscl Throm Vas Biol 29: 363–371. doi: 10.1161/ATVBAHA.108.178731
    [21] Subbanagounder G, Leitinger N, Shih PT, et al. (1999) Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: in vitro and in vivo inhibition by WEB-2086. Circ Res 85: 311–318. doi: 10.1161/01.RES.85.4.311
    [22] Knapp S, Matt U, Leitinger N, et al. (2007) Oxidized phospholipids inhibit phagocytosis and impair outcome in Gram-negative sepsis in vivo. J Immunol 178: 993–1001. doi: 10.4049/jimmunol.178.2.993
    [23] Marathe GK, Pandit C, Lakshmikanth CL, et al. (2014) To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase. J Lipid Res 55: 1847–1854. doi: 10.1194/jlr.R045492
    [24] Watson AD, Leitinger N, Navab M, et al. (1997) Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/ endothelial interactions and evidence for their presence in vivo. J Biol Chem 272: 13597–13607. doi: 10.1074/jbc.272.21.13597
    [25] Steinberg D, Parthasarathy S, Carew TE, et al. (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 320: 915–924.
    [26] Berliner JA, Heinecke JW (1996) The role of oxidized lipoproteins in atherogenesis. Free Radical Bio Med 20: 707–727. doi: 10.1016/0891-5849(95)02173-6
    [27] Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. (1989) Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84: 1086–1095. doi: 10.1172/JCI114271
    [28] Yang L, Latchoumycandane C, McMullen MR, et al. (2010) Chronic alcohol exposure increases circulating bioactive oxidized phospholipids. J Biol Chem 285: 22211–22220. doi: 10.1074/jbc.M110.119982
    [29] Lehr HA, Weyrich AS, Saetzler RK, et al. (1997) Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. J Clin Invest 99: 2358–2364. doi: 10.1172/JCI119417
    [30] Appleyard CB, Hillier K (1995) Biosynthesis of platelet-activating factor in normal and inflamed human colon mucosa: evidence for the involvement of the pathway of platelet- activating factor synthesis denovo in inflammatory bowel disease. Clin Sci 88: 713–717. doi: 10.1042/cs0880713
    [31] Marathe GK, Johnson C, Billings SD, et al. (2005) Ultraviolet B radiation generates platelet-activating factor-like phospholipids underlying cutaneous damage. J Biol Chem 280: 35448–35457. doi: 10.1074/jbc.M503811200
    [32] Stafforini DM (2009) Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drug Ther 23: 73–83. doi: 10.1007/s10557-008-6133-8
    [33] Bochkov VN, Philippova M, Oskolkova O, et al. (2006) Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. Circ Res 99: 900–908. doi: 10.1161/01.RES.0000245485.04489.ee
    [34] Silva AR, de Assis EF, Caiado LF, et al. (2002) Monocyte chemoattractant protein-1 and 5-lipoxygenase products recruit leukocytes in response to platelet-activating factor-like lipids in oxidized low-density lipoprotein. J Immunol 168: 4112–4120. doi: 10.4049/jimmunol.168.8.4112
    [35] Pontsler AV, StHilaire A, Marathe GK, et al. (2002) Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem 277: 13029–13036. doi: 10.1074/jbc.M109546200
    [36] Ricote M, Huang J, Fajas L, et al. (1998) Expression of the peroxisome proliferator-activated receptor gamma (PPAR-gamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. P Natl Acad Sci USA 95: 7614–7619.
    [37] Schonbeck U, Sukhova GK, Graber P, et al. (1999) Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155: 1281–1291. doi: 10.1016/S0002-9440(10)65230-3
    [38] Marathe GK, Zimmerman GA, Prescott SM, et al. (2002) Activation of vascular cells by PAF-like lipids in oxidized LDL. Vasc Pharmacol 38: 193–200. doi: 10.1016/S1537-1891(02)00169-6
    [39] Latchoumycandane C, Marathe GK, Zhang R, et al. (2012) Oxidatively truncated phospholipids are required agents of tumor necrosis factor alpha (TNF alpha)-induced apoptosis. J Biol Chem 287: 17693–17705. doi: 10.1074/jbc.M111.300012
    [40] Bochkov VN, Kadl A, Huber J, et al. (2002) Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 419: 77–81. doi: 10.1038/nature01023
    [41] Jeong YI, Jung ID, Lee CM, et al. (2009) The novel role of platelet-activating factor in protecting mice against lipopolysaccharide-induced endotoxic shock. PLoS One 4: e6503. doi: 10.1371/journal.pone.0006503
    [42] Eligini S, Brambilla M, Banfi C, et al. (2002) Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-kappa B/I kappa B and ERK2-dependent mechanisms. Cardiovasc Res 55: 406–415. doi: 10.1016/S0008-6363(02)00437-6
    [43] Oskolkova OV, Afonyushkin T, Preinerstorfer B, et al. (2010) Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation. J Immunol 185: 7706–7712. doi: 10.4049/jimmunol.0903594
    [44] Zimmerman GA, Renzetti AD, Hill HR (1984) Granulocyte adherence in pulmonary and systemic arterial blood samples from patients with adult respiratory distress syndrome. Am Rev Respir Dis 129: 798–804. doi: 10.1164/arrd.1984.129.5.798
    [45] Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular and molecularbiology. Annu Rev Biochem 69: 145–182. doi: 10.1146/annurev.biochem.69.1.145
    [46] Herschman HR (1996) Prostaglandin synthase 2. Biochim Biophys Acta 1299: 125–140. doi: 10.1016/0005-2760(95)00194-8
    [47] Maloney CG, Kutchera WA, Albertine KH, et al. (1998) Inflammatory agonists induce cyclooxygenase type 2 expression by human neutrophils. J Immunol 160: 1402–1410.
    [48] Marnett LJ, Rowlinson SW, Goodwin DC, et al. (1999) Arachidonic acid oxygenation by COX-1 and COX-2 Mechanisms of catalysis and inhibition. J Biol Chem 274: 22903–22906. doi: 10.1074/jbc.274.33.22903
    [49] Hoffmann E, Dittrich-Breiholz O, Holtmann H, et al. (2002) Multiple control of interleukin-8 gene expression. J Leukocyte Biol 72: 847–855.
    [50] Countryman NB, Pei Y, Yi Q, et al. (2000) Evidence for involvement of the epidermal platelet-activating factor receptor in ultraviolet-B-radiation-induced interleukin-8 production. J Invest Dermatol 115: 267–272. doi: 10.1046/j.1523-1747.2000.00058.x
    [51] Yost CC, Denis MM, Lindemann S, et al. (2004) Activated polymorphonuclear leukocytes rapidly synthesize retinoic acid receptor-alpha: a mechanism for translational control of transcriptional events. J Exp Med 200: 671–680. doi: 10.1084/jem.20040224
    [52] Matt U, Sharif O, Martins R, et al. (2015) Accumulating evidence for a role of oxidized phospholipids in infectious diseases. Cell Mol Life Sci 72: 1059–1071. doi: 10.1007/s00018-014-1780-3
    [53] Mathiak G, Szewczyk D, Abdullah F, et al. (1997) Platelet-activating factor (PAF) in experimental and clinical sepsis. Shock 7: 391–404. doi: 10.1097/00024382-199706000-00001
    [54] Fukuda Y, Kawashima H, Saito K, et al. (2000) Effect of human plasma-type platelet-activating factor acetylhydrolase in two anaphylactic shock models. Eur J Pharmacol 390: 203–207. doi: 10.1016/S0014-2999(99)00920-6
    [55] Giral M, Balsa D, Ferrando R, et al. (1996) Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock. Brit J Pharmacol 118: 1223–1231. doi: 10.1111/j.1476-5381.1996.tb15527.x
    [56] Suckling KE, Macphee CH (2002) Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque. Expert Opin Ther Tar 6: 309–314. doi: 10.1517/14728222.6.3.309
    [57] Mullard A (2014) GSK's darapladib failures dim hopes for anti-inflammatory heart drugs. Nat Rev Drug Discov 13: 481–482. doi: 10.1038/nrd4381
    [58] Riedemann NC, Ward PA (2002) Oxidized lipid protects against sepsis. Nat Med 8: 1084–1085. doi: 10.1038/nm1002-1084
    [59] Matt U, Sharif O, Martins R, et al. (2013) WAVE 1 mediates suppression of phagocytosis by phospholipid-derived DAMPs. J Clin Invest 123: 3014–3024. doi: 10.1172/JCI60681
    [60] Jacob SP, Lakshmikanth CL, Chaithra VH, et al. (2016) Lipopolysaccharide cross-tolerance delays platelet-activating factor induced sudden death in Swiss albino mice: involvement of cyclooxygenase in cross- tolerance. PLoS One: e0153282.
    [61] Leitinger N, Tyner TR, Oslund L, et al. (1999) Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. P Natl Acad Sci USA 96: 12010–12015.
    [62] Watanabe J, Marathe GK, Neilsen PO, et al. (2003) Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles. J Biol Chem 278: 33161–33168. doi: 10.1074/jbc.M305321200
    [63] Stafforini DM, Elstad MR, McIntyre TM, et al. (1990) Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem 265: 9682–9687.
    [64] Uhlson C, Harrison K, Allen CB, et al. (2002) Oxidized phospholipids derived from ozone-treated lung surfactant extract reduce macrophage and epithelial cell viability. Chem Res Toxicol 15: 896–906. doi: 10.1021/tx010183i
    [65] Dahl M, Bauer AK, Arredouani M, et al. (2007) Protection against inhaled oxidants through scavenging of oxidized lipids by macrophage receptors MARCO and SR-AI/II. J Clin Invest 117: 757–764. doi: 10.1172/JCI29968
    [66] Podrez EA, Febbraio M, Sheibani N, et al. (2000) Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 105: 1095–1108. doi: 10.1172/JCI8574
    [67] Chen M, Masaki T, Sawamura T (2002) LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Therapeut 95: 89–100. doi: 10.1016/S0163-7258(02)00236-X
    [68] Teixeira-da-Cunha MG, Gomes RN, Roehrs N, et al. (2013) Bacterial clearance is improved in septic mice by platelet-activating factor-acetylhydrolase (PAF-AH) administration. PLoS One 8: e74567. doi: 10.1371/journal.pone.0074567
    [69] Chen CH, Jiang T, Yang JH, et al. (2003) Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 107: 2102–2108. doi: 10.1161/01.CIR.0000065220.70220.F7
  • Reader Comments
  • © 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(3919) PDF downloads(1110) Cited by(1)

Article outline

Figures and Tables

Figures(3)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog